Phase III Adult Stem Cell Company Reports Positive Data Through “Right to Try” Accelerated Access Collaboration
Therapeutic Solutions International (TSOI) announced today preliminary results of a collaboration with the Veltmeyer Institute for Advanced Therapeutics aimed at providing patients with protocols, products and cells, developed by the Company. As part of the collaboration, the Veltmeyer Institute provided an update on the first three patients treated.
“In patients with neurodegenerative diseases such as ALS (Amyotrophic lateral sclerosis), there is a correlation between survival and the number of T-regulatory cells that can actually produce nerve protective growth factors. In the case of our ALS patient, in addition to physical improvements, an increase in T-regulatory cells after stem cell therapy was observed at an astounding level from 47% pre-treatment to 77% post-JadiCell infusion treatment. Another case we treated was that of a 5 1/2-year-old boy diagnosed with autism who has literally not spoken a single word since birth. After JadiCell infusion, he is now actually talking for the first time in his life. Treatment of the schizophrenic patient demonstrated some degree of improvement,” said Dr. James Veltmeyer, Chief Medical Officer of the Company, and Founder of the Veltmeyer Institute.
“We are committed to taking our stem cell therapies through the normal regulatory processes with the FDA,” said Timothy Dixon, President, and CEO of the Company. “With that being said, as a corporation we have a moral and social responsibility to provide access to promising treatments as fast and ethically as possible. Therefore we are pleased to collaborate with the Veltmeyer Institute to make stem cell therapy affordable and accessible to the vast majority of people needing such treatment. If we can reach this goal, we will have made another gigantic stride toward healing people of some of the most destructive diseases to plague mankind.”
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221205005372/en/
Contacts
Timothy G. Dixon
ir@tsoimail.com
